source
- FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravisThe Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…
- Isomorphic Labs partners with Merck on AI-driven oncology drug discovery after $5 billion funding roundIsomorphic Labs announced a new collaboration with Merck & Co., adding the pharma giant to its AI drug discovery partners. The agreement follows Isomorphic's recent $5 billion financing and will f…